Brilaroxazine - Reviva Pharmaceuticals
Alternative Names: brilaroxazine lipogel; RP 5000; RP-5063Latest Information Update: 12 Jul 2024
At a glance
- Originator Reviva Pharmaceuticals
- Class Antidepressants; Antifibrotics; Antipsoriatics; Antipsychotics; Behavioural disorder therapies; Benzoxazines; Chlorobenzenes; Ethers; Ketones; Mood stabilisers; Piperazines; Small molecules
- Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Dopamine D4 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor partial agonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- Phase II Schizoaffective disorder
- Phase I Attention-deficit hyperactivity disorder; Bipolar disorders; Idiopathic pulmonary fibrosis; Major depressive disorder; Pulmonary arterial hypertension
- Preclinical Psoriasis
- Discontinued Autistic disorder; Gilles de la Tourette's syndrome
Most Recent Events
- 09 Jul 2024 Reviva Pharmaceuticals has patent protection for Brilaroxazine in European Union
- 29 May 2024 Brilaroxazine is still in phase I trials for Attention-deficit hyperactivity disorder in an Unknown location (Reviva Pharmaceuticals pipeline, June 2024)
- 29 May 2024 Brilaroxazine is still in phase I trials for Bipolar disorders in an Unknown location (Reviva Pharmaceuticals pipeline, June 2024)